CDSCO Approves India's First Dengue Vaccine
The Drugs Controller General of India has granted market authorisation for Takeda Biopharmaceuticals' QDENGA for individuals aged four to 60, regardless of prior infection or screening requirements.
India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has approved QDENGA, the country's first dengue vaccine, manufactured by Takeda Biopharmaceuticals. The clearance marks a significant addition to national prevention efforts against the mosquito-borne disease.
CDSCO approved India's first dengue vaccine QDENGA.
PIBPrimary
sourceQDENGA is manufactured by Takeda Biopharmaceuticals.
Google News India · PIB · Reuters IndiaPrimary
sourceDCGI granted market authorisation for QDENGA.
Google News IndiaQDENGA is approved for individuals aged 4 to 60 years.
Google News IndiaQDENGA can be given regardless of prior dengue infection.
Google News IndiaQDENGA does not require pre-vaccination screening.
Google News IndiaQDENGA is a live-attenuated tetravalent vaccine (TAK-003).
Google News IndiaQDENGA protects against all four dengue serotypes.
Google News IndiaQDENGA is administered in two doses three months apart.
Google News IndiaQDENGA has been approved in 43 countries since 2022 launch.
Google News IndiaOver 32 million doses of QDENGA distributed globally.
Google News IndiaIndia reported over 233,000 dengue cases in 2024.
Google News IndiaIndia accounts for about one-third of global dengue burden.
Google News IndiaTakeda has not announced official price for QDENGA in India.
Google News India
Google News India·PIB·Reuters India